EGFR mutations in non small cell lung cancer patients in South Africa by Chan, Sze Wai
i 
 
EGFR MUTATIONS IN NON SMALL CELL LUNG 
CANCER PATIENTS IN SOUTH AFRICA 
 
 
 
Sze Wai Chan 
 
 
 
 
A research report submitted to the Faculty of Health Sciences, University of the 
Witwatersrand, Johannesburg, in partial fulfillment of the requirements for the degree of 
Master of Medicine in the branch of Internal Medicine / Medical Oncology. 
 
 
Johannesburg 
1st September 2014 
ii 
 
DECLARATION 
 
I, Sze Wai Chan declare that this research report is my own work.  It is being submitted 
for the degree of Master of Medicine in Internal Medicine / Medical Oncology in the 
University of the Witwatersrand, Johannesburg.  It has not been submitted before for 
any degree or examination at this or any other University. 
 
 
         
      
         
 
  
  
 
 
iii 
 
DEDICATION 
 
This work is dedicated to my loving parents 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iv 
 
ABSTRACT 
Introduction: Tyrosine kinase inhibitors and EGFR mutations has changed the 
treatment approach to lung cancer globally.  This retrospective study will look at factors 
associated with EGFR mutations and define the EGFR mutation rate in South Africa. 
Methods: Retrospective record review from NSCLC patients in South Africa who were 
tested for EGFR mutations at Lancet Laboratories during 1st September 2009 to 30th 
June 2012.  Chi-squared test was used to determine association with categorical 
variables. Kaplan- Meier survival analysis was done for OS and PFS between EGFR 
mutation positive and negative patients.  Cox proportional hazards were used for 
subgroup analysis.  Treatment practices and response were described.   
Results: 170 lung cancer samples were evaluable for EGFR mutation and 37 were 
EGFR mutation positive (21.8%).  There were 22 (59.5%) exon 19 deletions, 11 (29.7%) 
L858R mutations, two G719X mutations, one S768I mutation and one exon 20 insertion. 
The median age was 63 (range 27-85).  There were more females (55.6%) than males 
(44.4%) sent for mutation testing.  Most patients were whites (71%), followed by blacks 
(18.3%), and other race (10.7%). 85% of all NSCLC samples tested were 
adenocarcinoma. None of the squamous cell carcinoma tested was positive for EGFR 
mutation.  Smoking status was inversely proportional to EGFR mutation status 
(p<0.001). Over 60% patients received chemotherapy first and second line and 
responses decreased with each line of chemotherapy.  Median PFS and OS were not 
different between the EGFR mutation positive and negative groups (6.85 versus 6.8 
months; HR 1.6; 95% CI 0.70-3.65; p=0.2543 and 11.5 versus 12.9 months; HR 0.70; 
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95% CI 0.28-1.75; p=0.44, respectively).   On multivariate analysis, only non-white race 
was associated with decrease in OS (HR 6.66; 95% CI 2.31-19.19; p=0.0004). 
Conclusion: EGFR mutation rate in South African lung cancer patients was 21.8%. 
89% of all EGFR mutations were either exon 19 deletions or L858R point mutations.  
Most EGFR mutations were associated with adenocarcinoma of the lung in non-
smokers. These findings were consistent with current literature in western countries. 
Treatment practice remained chemotherapy based, with few patients receiving EGFR 
TKIs. Efforts should be made to prioritized targeted treatment approach in lung cancer 
in South Africa. 
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Smoking status was defined according to the IPASS and the Spanish screening study 
from Rosell et al (21, 23). 
NEVER SMOKERS: < 100 lifetime cigarettes 
FORMER SMOKERS: ≥ 1 year since cessation 
CURRENT SMOKERS: Still smoking, or < 1 year since cessation 
FORMER LIGHT SMOKERS: stopped smoking at least 15 years previously and had a 
total of ≤ 10 pack-years of smoking 
RESPONSE RATE: Measured by Response Evaluation Criteria in Solid Tumours 
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OVERALL SURVIVAL (OS): From the date of first treatment until death from any cause 
LOST TO FOLLOW UP: Patient did not return for follow up visits AND unable to contact 
patient by telephonic means in 3 separate consecutive occasions 
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SASMO: South African Society of Medical Oncology 
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